

Reconstruction of the Aortic Valve and Root: A Practical Approach  
September 13<sup>th</sup>-15<sup>th</sup>, 2017, Homburg/Saar, Germany

# ***The Role Of Ross Operation In Aortic Insufficiency***

Laurent de Kerchove, MD, PhD

Cliniques Universitaires St-Luc, IREC, UCL

Brussels, Belgium



Cliniques universitaires  
**SAINT-LUC**  
UCL BRUXELLES

**UCL**  
Université  
catholique  
de Louvain




I.		II.		III.		IV.	
I have received (a) research grant(s) / in kind support		I have been a speaker or participant in accredited CME/CPD ...		I have been a consultant / strategic advisor etc. ...		I am a holder of (a) patent / shares / stocks or ownership...	
A		A		A		A	
... from current sponsor(s)		... from current sponsor(s)		... for current sponsor(s)		... <u>related</u> to presentation	
YES	NO	YES	NO	YES	NO	YES	NO
<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
B		B		B		B	
... from any institution		... from any institution		... for any institution		... <u>not related</u> to presentation	
YES	NO	YES	NO	YES	NO	YES	NO
<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

**SCORE: 1234**

# Replacement of Aortic and Mitral Valves with a Pulmonary Autograft

Ross DN    *Lancet* 1967 Nov 4;2(7523):956-8




- Indicated in pediatric and young adult population ( $\leq 55$  years) suffering from AS and/or AI
- No anticoagulation, growth potential
- Excellent exercise tolerance

*Doty et al. Asian Cardiovasc Thorac Ann* 1999


*Porter et al. JHVD* 1999

# Ross operation in AI: Ross techniques


Freestanding Root



Subcoronary




Inclusion cylinder




# Ross operation in AI: Why perform a Ross

- Low operative mortality ( $\leq 1\%$ )
- Excellent survival up to 20 y = to general population matched for age and sex




T. David et al. J Thor Cardiovasc Surg 2014




H-H. Sievers et al. Eur J Cardiothorac Surg 2015

# Ross operation in AI: Why perform a Ross

- Excellent survival up to 20 y, = to general population matched for age and sex



Ismail El-hamamsy et al. Lancet 2010




S. Mastrobuoni et al. EJCTS 2015




# Ross operation in AI: Why perform a Ross

- Durability of PA: 80-90% freedom from reoperation at 20 years.




T. David et al. J Thor Cardiovasc Surg 2014;147 (1): 85-94



H-H. Sievers et al. Eur J Cardiothorac Surg 2015;ejcts.ezv001

# Ross operation in AI: When Compared to Alternatives


- Lower reoperation rates compared to bioprosthesis in young adults






# Ross operation in AI: When Compared to Alternatives

- Compared to Mechanical Valve Replacement (mAVR) – Matched Cohorts:
  - Better overall survival



After adjusting for age, the Hazard Ratio of late death is 0.37 (95% CI: 0.17-0.79) for the Ross operation compared to M-AVR


*S. Mastrobuoni – Presented at HVS Meeting 2014*




*Mazine A et al. Circulation. 2016*

# Ross operation in AI: When Compared to Alternatives

- Compared to mAVR:
  - Higher hemorrhagic and thromboembolic in mAVR




*S. Mastrobuoni – Presented at HVS Meeting 2014*




*Mazine A et al. Circulation. 2016*

# Ross operation in AI: When Compared to Alternatives

- Compared to Mechanical Valve Replacement (mAVR) – Matched Cohorts:
  - Non-significant in term of reoperation




*S. Mastrobuoni – Presented at HVS Meeting 2014*



*Mazine A et al. Circulation. 2016*

# Ross operation in AI: When the Ross fails...

## Brussels Experience: Reoperations




Freedom from Autograft Reoperation (n=31)

• Sievers	87%	15y
• David	82%	20y
• <b>Chambers</b>	<b>88%</b>	<b>10y</b>
• <b>Kouchoukos</b>	<b>75%</b>	<b>10y</b>
• <b>Klieverik</b>	<b>69%</b>	<b>13y</b>

# Ross operation in AI: When the Ross fails...

Brussels Experience: Reoperations, mechanisms of failure

Sinus Valsalva diameter



David T., JTCVS. 2000

Mechanisms	n=31	Root Technique n=24 (%)	Inclusion Technique n=7 (%)
Proximal aorta dilatation ( $\pm$ AI)	24 (77)	21 (88)	3 (43)
Autograft Insufficiency	7 (23)	3 (12)	4 (57)

de Kerchove L, Ann Thorac Surg 2009

# Ross operation in AI: **When the Ross fails...**

## Risk Factors of Failure (autograft dilatationAI)

- Preoperative AI
- Dilated Annulus, Root or Asc Ao preop (= suppleness of proximal support)
- BAV (because large annulus/root/asc aorta!!!)
- Root Technique (++ long autograft)
- Older age
- Male Gender
- Postoperative Hypertension (*unproven*)

*Takkenberg J, J Heart Valve Dis 2006*

*Hanke T. Circulation 2007*


*de Kerchove L, Ann Thorac Surg 2009*


*Takkenberg J. Circulation 2009*

*David TE. J Thorac Cardiovasc Surg 2014*

*Skillington P. JTCVS 2015*









# Ross operation in AI: When the Ross fails...

## Repair options and results

### European multicenter experience with valve-sparing reoperations after the Ross procedure

Aart Mookhoek, MD,<sup>a</sup> Laurent de Kerchove, MD,<sup>b</sup> Gebrine El Khoury, MD,<sup>b</sup> Timo Weimar, MD,<sup>c</sup> Giovanni Battista Luciani, MD,<sup>d</sup> Alessandro Mazzucco, MD,<sup>d</sup> Ad J. J. C. Bogers, MD, PhD,<sup>a</sup> Diana Aicher, MD,<sup>c</sup> Hans-Joachim Schäfers, MD, PhD,<sup>c</sup> Efstratios I. Charitos, MD, PhD,<sup>f</sup> Ulrich Stierle, MD,<sup>f</sup> and Johanna J. M. Takkenberg, MD, PhD<sup>a</sup>

- 86 pts, 6 centers
- 1% hosp. mortality





TABLE 4. Univariable analysis of the hazard of reintervention after valve-sparing reoperation


Variable	Hazard ratio (95% CI)	P value
Ross technique		
Full root	1.000	
Inclusion cylinder	4.358 (1.454-13.064)	.009
Subcoronary	4.005 (0.497-32.286)	.193
Age	0.944 (0.906-0.985)	.007
Isolated aortic regurgitation (as repair indication)	5.021 (1.721-14.649)	.003
Severe aortic regurgitation (grade $\geq 3$ )*	3.736 (1.165-11.978)	.027
Isolated autograft valve repair	5.041 (1.677-15.154)	.004
Valve-sparing autograft root replacement	0.199 (0.070-0.565)	.002

CI, Confidence interval. \*At the time of valve-sparing reoperation after Ross procedure.

# Ross operation in AI: Root dilat + AI is best Repaired ...


## Freedom from Reoperation

*Reimpl. & Remod.*




*T. David JTCVS 2014*

*Remodeling*



*H-J Schafers EJCTS 2015*







*Reimplantation*





*Brussels group updated 2017*

**Durable !**

# Ross operation in AI: **AI is best repaired ... But**

AI Class	Type I Normal cusp motion with FAA dilatation or cusp perforation				Type II Cusp Prolapse	Type III Cusp Restriction
	Ia	Ib	Ic	Id		
Mechanism						







Mitigated results in retracted valves (Type III AI following el Khoury Classification)



# Ross operation in AI: Retracted Valve Type III Etiologies

- Retracted Valve Etiologies

- ✓ Rheumatic
- ✓ Degenerative calcification
- ✓ Bicuspid
- ✓ Quadricuspid
- ✓ Unicuspid
- ✓ Dysmorphic









# Ross operation in AI: Retracted Valve Type III Etiologies


Often Repaired with Patch

- Retracted Valve Etiologies


- ✓ Rheumatic
- ✓ Degenerative calcification
- ✓ Bicuspid
- ✓ Quadricuspid
- ✓ Unicuspid
- ✓ Dysmorphic



# Ross operation in AI: Retracted Valve Type III Etiologies





*Boodhwani M. JTCVS 2010*



*Aicher D. Circ. 2011*

# Ross operation in AI: Retracted Valve Type III Etiologies

- 1988-1995: 94 pts, mean age 30y, 84% rheumatic etiology




# Ross operation in AI: **Need for Reinforcement**


**In Retracted valve Type III AI or any other AI judged non reparable,  
the Ross procedure is an option.**




**Autograft need to be reinforced in those cases**



*H. Sievers, 2<sup>nd</sup> North American Aortic  
Valve repair Symposium, 2016*




*Skillington et al., JTCVS 2015*





*Carrel et al., JTCVS 2008  
El Khoury et al., Presented at HVS 2017*

# Ross operation in AI: **Need for Reinforcement**



*Root Reinforcement: German-Dutch Ross Registry*







# Ross operation in AI: **Need for Reinforcement**

## *Autologous Root Reinforcement: Melbourne Experience*

20 yr experience (1992-2012):

- 310 patients, **1/3 AI**, 1/2 AS, 1/5 AI+AS,
- **92% BAV**
- **Modified Inclusion** technique
- **± annulus/root/Asc Ao** reduction







# Ross operation in AI: **Need for Reinforcement**



## *Autologous Root Reinforcement: Melbourne Experience*





# Ross operation in AI: **Need for Reinforcement**

## *Autologous Root Reinforcement: Melbourne Experience*

322 Ross:    - **96% Freedom from reoperation @ 18 Yrs**

- **AI remains a risk factor for recurrent AR or AVR ! (n=11 only)**




TABLE 2. Risk factors associated with aortic sinus diameter during follow-up

Factor	Estimate $\pm$ SE	P	Reliability
Preoperative aortic sinus diameter	0.005195 $\pm$ 0.001405	<.001	86%
Male (vs female)	0.03776 $\pm$ 0.01415	.008	20%
Autograft diameter	0.01848 $\pm$ 0.004579	<.001	100%
Enlargement of sinotubular diameter at the time of surgery	0.04055 $\pm$ 0.02006	.044	89%
Aortic annulus diameter	0.006023 $\pm$ 0.002162	.006	100%
AS (vs AR and AR/AS)	-0.02847 $\pm$ 0.01099	.010	91%

AR, Aortic regurgitation; AS, aortic stenosis; SE, standard error.

# Ross operation in AI: **Need for Reinforcement**




## *Dacron Graft Reinforcement: Lille Experience*

12 pts (2003 - 2007):

- All BAV
- No mortality
- 1 reoperation (false aneurysm proximal suture line)
- FU No Grade 2+ AI

**TABLE 2.** Echocardiographic autograft diameter

Measurement level	Discharge (mm)	Last control (mm)	<i>P</i>
Annulus	23.3 ± 2.6	24.0 ± 1.9	.32
Neosinuses	32.6 ± 3.3	33.6 ± 3.3	.08
Sinotubular junction	28.9 ± 4.5	29.5 ± 3.6	.25




# Ross operation in AI: **Need for Reinforcement**

## *Dacron Graft Reinforcement: Bern Experience*

22pts (2006 - 2016):

- No mortality
  - 1 reoperation
- ➔ 4.5% at 10 years
- No Neo-aortic dilatation
  - No AI in 15 patients and stable AI Grade I in 6 patients






# Ross operation in AI: **Need for Reinforcement**

## *Dacron Graft Reinforcement: Brussels Experience*

76 pts (2011 - 2016):

- Indication: large aortic annulus ( $31 \pm 5$  mm) /aorta
- Inclusion in Valsalva® or Cardioroot® graft
- Graft size 28 – 30 mostly
- No mortality
- Autograft reoperations 4 pts (5%)
- FU AI grade 2+ 5 pts (6%)



# Ross operation in AR: Conclusions

- Ross operation bring survival and event-free survival advantages compared to mechanical and bioprosthesis in selected young patients
- In AI or mixed AI/AS etiologies (unsuitable for AV repair), Ross technique can be used but must be adapted to the anatomical characteristics of AI consisting in the presence of a large annulus/Root/asc Ao) otherwise the risk of failure increase significantly in those indications. Adaptation consist in the reinforcement of the autograft with stabilization and eventually reduction annuloplasty of the AVJ and the STJ.



*Thank you*



**UCL**

Université  
catholique  
de Louvain



# Ross operation in AI: Why perform a Ross

*“The pulmonary autograft is autologous, living and has a similar development, anatomy and histology of the aortic valve giving reason to use the pulmonary valve for aortic valve replacement – The Ross operation”*

*But there are some special issues to be considered:*

- a) The autograft has **no fibrous annulus**. manageable (intra-annular implantation)
- b) The pulmonary valve is transplanted from **low pressure** circulation to systemic pressure. adaptation seems possible
- b) The pulmonary valve is **surgically manipulated**.
- c) Necessitates the replacement of the pulmonary valve with a homograft converting a one valve disease to a potential **two valve problem**.

**Proteolytic enzyme expression in pulmonary autografts compared with that seen in normal valves.**

*Rabkin-Aikawa E et al. J Thorac Cardiovasc Surg. 2004;128:552-61.*



**Immunophenotype of endothelial cells of normal valves and autograft explants.**

*x: Arterial endothelial cell marker*

**For the leaflets there seems to be some kind of adaptation.**

**Adaptation of pulmonary leaflets to systemic pressure**

**x**



# Ross operation in AI: When the Ross fails...

- Predictor Factors of Failure

*Table 3. Univariate and Multivariate Analyses*

Variable	Odds Ratio	95% CI	p Value
Predictors of proximal aorta dilatation ( $\geq 45$ mm)			
Univariate			
Male sex	2.9	1–8.7	0.04
Preoperative AV regurgitation	2.9	1.4–6.2	0.003
Preoperative AV disease	0.4	0.2–1	0.04
Root technique	4.7	1.6–14	0.003
Follow-up length (month)*	—	—	0.001
Multivariate			
Preoperative AV regurgitation	3.8	1.9–7.9	0.004
Root technique	7	2.7–18.3	0.003
Follow-up length (month)*	1.02	1.01–1.03	0.003
Predictors of moderate or greater autograft regurgitation			
Univariate			
Male sex	3.6	1.2–10.7	0.01
Preoperative AV regurgitation	2.1	1–4.3	0.04
Proximal aorta dilatation ( $\geq 45$ mm) at follow-up	4.2	1.9–9.1	0.0002
Multivariate			
Male sex	3.1	1.0–9.3	0.045
Proximal aorta dilatation ( $\geq 45$ mm) at follow-up	3.7	1.7–8.3	0.0007

# Ross operation in AI: When the Ross fails...

- Predictor Factors of Failure



**TABLE 3. Risk Factors for Autograft Dilatation**

Cox proportional hazard	Beta factor	Standard Error	P
Age	−0.07	0.04	0.05
Preoperative sinus Valsalva diameter	0.24	0.12	0.02
Root replacement technique	2.80	1.27	0.03
Pericardial strip buttressing	−2.61	1.33	0.04

**TABLE 4. Risk Factors for Autograft Dysfunction**

Cox proportional hazard	Beta Factor	Standard Error	P
Sex (female)	3.51	1.14	0.002
Preoperative Sinus Valsalva diameter	0.34	0.16	0.04
Follow-up Sinus Valsalva diameter	0.63	0.21	0.003
Follow-up sinotubular junction diameter	0.77	0.32	0.02

*Luciano et al. Circ 2003*



*Kouchoukos et al. ATS 2004*

# Ross operation in AI: When the Ross fails...

- Brussels Experience: Multivariate Predictors

## Aortic Insufficiency



<u>Predictors</u>	<u>P value</u>	<u>Hazard ratio</u> <u>(95% CI)</u>
Age	0.001	1.04 (1-1.06)
Preoperative aortic valve insufficiency	0.001	3 (1.6-5.7)
Preoperative ascending aorta dilatation	0.02	2.8 (1.1 - 6.7)

## Proximal Aorta Dilatation

<u>Predictors</u>	<u>Multivariate</u> <u>P-value</u>	<u>Hazard ration</u> <u>(95% CI)</u>
Root replacement technique	0.001	5.7 (2-16.5)
Preoperative aortic valve insufficiency	0.001	2.8 (1.5 - 5.1)
Preoperative ascending aorta dilatation	0.002	4.3 (1.7 – 10.6)
Age	0.007	1.03 (1 – 1.06)
Male gender	0.04	2.5 (1 - 6)

# Ross operation in AI: **AI is best repaired ...**

## Freedom from Reoperation after AV Repair





# Ross operation in AI: Retracted Valve Type III Etiologies


## Patch and AV Reoperation

**TABLE 2. Risk factors by multivariate Cox regression analysis (–2 log-likelihood function = 161.87, chi-square = 72.79,  $P < .001$ )**


Variable	<i>P</i> value	HR	95% CI
Diameter of AV junction (mm)	<.001	1.43	1.21-1.69
Use of annuloplasty	.01	1.28	1.89-66.26
Myocardial ischemia (min)	.04	0.96	0.93-1.00
Effective height	<.001	0.58	0.43-0.79
Use of pericardial patch	<.001	6.24	2.30-16.90

AV, Aortoventricular; CI, confidence interval; HR, hazard ratio.





# Ross operation in AI: Patch in Non-Retracted Valves



*H.J. Schäfers et al. J Thorac Cardiovasc Surg 2010*




*Z. Mosala Nezhad et al. Eur J Cardiothorac Surg. 2014*



# Ross operation in AI: **When the Ross fails...**


Mechanisms of failure in different techniques



autograft dilatation +/- AI



AI (autograft distortion)



AI (autograft distortion)